New radioactive drug takes aim at Hard-to-Treat prostate cancer

NCT ID NCT07581184

Recruiting now Disease control Sponsor: Aktis Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 5 times

Summary

This early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug can slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B7-H3 radiopharmaceutical ([225Ac]Ac-AKY-2519)
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is an early Phase 1b trial, so the main goal is safety, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B7H3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B7H3 CASTRATION RESISTANT METASTATIC PROSTATE CANCER MCRPC MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) PROSTATE CANCER

Contacts and locations

Show contact details

Locations

BAMF Health
RECRUITING

Grand Rapids, Michigan, 49503, United States

Contact Email: •••••@•••••
Biogenix Molecular, LLC
RECRUITING

Miami, Florida, 33165, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Irvine, California, 92618, United States
XCancer
RECRUITING

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.